| Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial | |
| Wang, Aihua; Hilger, James; Huang, Jane; Novotny, William; Osman, Muhtar; Zhu, Jun; Hu, Jianda; Song, Yuqin; Zhou, Keshu; Zou, Dehui | |
| 刊名 | BLOOD
 |
| 2018 | |
| 卷号 | 132 |
| ISSN号 | 0006-4971 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3534198 |
| 专题 | 吉林大学白求恩第一医院 |
| 推荐引用方式 GB/T 7714 | Wang, Aihua,Hilger, James,Huang, Jane,et al. Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial[J]. BLOOD,2018,132. |
| APA | Wang, Aihua.,Hilger, James.,Huang, Jane.,Novotny, William.,Osman, Muhtar.,...&Guo, Haiyi.(2018).Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial.BLOOD,132. |
| MLA | Wang, Aihua,et al."Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial".BLOOD 132(2018). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论